Autoimmune GFAP astrocytopathy: Prospective evaluation of 90 patients in 1 year

Divyanshu Dubey, Shannon R. Hinson, Evan A. Jolliffe, Anastasia Zekeridou, Eoin P. Flanagan, Sean J. Pittock, Eati Basal, Daniel A. Drubach, Daniel H. Lachance, Vanda A. Lennon, Andrew McKeon

Research output: Contribution to journalArticlepeer-review

31 Scopus citations


In this prospective evaluation of serum and CSF samples, all but two CSF GFAPα-IgG positive patients had autoimmune meningoencephalomyelitis while serum GFAPα-IgG positivity alone was less specific. Phenotypes were diverse among patients that were serum positive only. Adult and pediatric clinical presentations were similar. Most patients were immunotherapy responsive. Co-existing NMDA-R-IgG and cancer were associated with lack of response to first-line immunotherapy. Among patients with follow-up information, 18% had relapses. This study demonstrates CSF GFAPα-IgG is a specific autoimmune meningoencephalomyelitis biomarker, with favorable corticosteroid response. Lack of response should prompt evaluation for co-existing NMDA-R-IgG or malignancy.

Original languageEnglish (US)
Pages (from-to)157-163
Number of pages7
JournalJournal of neuroimmunology
StatePublished - Aug 15 2018


  • Autoimmune
  • Cerebrospinal fluid
  • Glial fibrillary astrocytic protein
  • Meningoencephalomyelitis
  • Pediatric

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Autoimmune GFAP astrocytopathy: Prospective evaluation of 90 patients in 1 year'. Together they form a unique fingerprint.

Cite this